Pilot program to reimburse patients for hemp-derived products could be undermined by ban passed by Congress
The Centers for Medicare and Medicaid Services recently started a new pilot to reimburse patients for hemp-derived products – like CBD – but a hemp ban that Congress passed in November could derail the program.
The new program will make certain Medicare and Medicaid recipients eligible for reimbursement for up to $500 worth of hemp products each year and is intended in part to evaluate whether these products could reduce their other health related costs.